Seer, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. The filing reports annual results; standalone fourth-quarter results are not provided in the supplied text.
Business context
Seer develops and sells the Proteograph Product Suite, a research-use-only proteomics platform combining engineered nanoparticle consumables, an SP100 automation instrument and software. The company is in the early stages of commercialization and is investing in product development, manufacturing and market adoption. It shipped 23 instruments in 2023, bringing cumulative shipments to 62.
Financial performance and liquidity
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Revenue | $16.7 million | $15.5 million | Up 8% |
| Gross profit / margin | $8.5 million / 51.1% | $7.1 million / 45.8% | Margin up 5.3 percentage points |
| Operating expenses | $112.0 million | $104.3 million | Up 7% |
| Operating loss | $(103.5) million | $(97.2) million | Loss widened |
| Net loss | $(86.3) million | $(93.0) million | Loss narrowed 7% |
| Net loss per share, diluted | $(1.35) | $(1.49) | Improved |
| Cash used in operating activities | $(59.1) million | $(60.8) million | Outflow decreased |
Revenue growth reflected higher service and grant revenue; product revenue was essentially flat at $8.5 million. PrognomiQ, a related party, contributed $4.7 million, or 28% of revenue, versus 32% in 2022. Gross margin improved partly because service revenue, which has lower cost of revenue, increased. Higher R&D spending—up 16% to $53.0 million—contributed to the larger operating loss. Interest income rose to $17.8 million from $4.6 million and helped reduce the net loss; it does not reflect improved operating profitability.
At year-end, cash and cash equivalents were $32.5 million and investments were $340.6 million, totaling $373.1 million. Total assets were $436.3 million, total liabilities $39.4 million, and stockholders’ equity $396.9 million. The balance sheet presents no borrowings; operating lease liabilities totaled $28.3 million. Operating cash burn was $59.1 million, and capital expenditures were $7.3 million. Management states available cash, cash equivalents and investments should fund operations for at least 12 months from issuance of the financial statements, while expecting continuing losses and no positive operating cash flow for the foreseeable future.
Changes, outlook and notable matters
- Total revenue increased modestly, while operating expenses grew faster and operating losses widened. Net loss narrowed mainly because of higher interest income.
- Management expects continued significant losses and increased expenses associated with commercialization, hiring, manufacturing capacity, product development and public-company operations. The filing provides no specific revenue or earnings guidance.
- In August 2023, Seer announced a workforce reduction affecting approximately 12% of full-time employees and other expense-reduction measures; benefits may not meet expectations.
- Customer concentration is material: PrognomiQ accounted for 28% of 2023 revenue. Seer also held approximately 15% of PrognomiQ, but its equity-method investment had a zero carrying value at year-end after recognizing its share of losses.
- Seer relies on Hamilton Company as the sole contract manufacturer of its SP100 instruments and identifies supplier, manufacturing, product-quality and commercialization risks.
- Products are marketed for research use only. Regulatory treatment could change if authorities determine products are intended for diagnostic use; proposed FDA changes to oversight of laboratory-developed tests add uncertainty.
- A December 2023 lawsuit alleges wrongful exclusion of an inventor on certain patents licensed from Brigham and Women’s Hospital. The filing also states that Seer was not party to material legal proceedings; investors should clarify the lawsuit’s status and potential significance.
- The company reported $34.4 million of stock-based compensation. It also disclosed $6.3 million of supplier purchase commitments at year-end.
Important facts for investors to verify
- Whether instrument shipments translate into recurring consumables use and sustained revenue growth, and how the customer pipeline and utilization are progressing.
- How much revenue and receivables depend on PrognomiQ, including its financial position, future purchasing plans and commercial relationship with Seer.
- Whether the $373.1 million liquidity balance and management’s stated 12-month runway remain adequate given operating cash burn, planned investment and any additional cost reductions.
- The drivers of gross-margin improvement and whether it can persist as product and consumables sales scale.
- The status and potential consequences of the patent inventorship lawsuit, key licensed intellectual-property rights and any potential regulatory changes affecting RUO products.
- Share dilution from outstanding options and restricted stock units; the filing reports 15.9 million potentially dilutive securities excluded from diluted loss per share as anti-dilutive.